Table 3 Relationship between LIPC expression and clinicopathological features of 90 patients with HCC
From: Downregulation of TUSC3 promotes EMT and hepatocellular carcinoma progression through LIPC/AKT axis
LIPC expression | |||||
|---|---|---|---|---|---|
Features | n | Negative | Positive | χ2 | P value |
Age (years) | |||||
 ≤ 50 | 34 | 27 (79.4%) | 7 (20.6%) | 3.386 | 0.066 |
 > 50 | 56 | 34 (60.7%) | 22 (39.3%) | ||
Gender | |||||
 Male | 79 | 53 (67.1%) | 26 (32.9%) | 0.141 | 0.708 |
 Female | 11 | 8 (72.7%) | 3 (27.3%) | ||
Tumor size (diameters) (cm) | |||||
 ≤ 5 | 40 | 21 (52.5%) | 19 (47.5%) | 7.695 | 0.006 |
 > 5 | 50 | 40 (80.0%) | 10 (20.0%) | ||
Number of tumors | |||||
 = 1 | 67 | 41 (61.2%) | 26 (38.8%) | 5.203 | 0.023 |
 > 1 | 23 | 20 (87.0%) | 3 (13.0%) | ||
Differentiation | |||||
 Poor | 26 | 19 (73.1%) | 7 (26.9%) |  |  |
 Moderate | 54 | 40 (74.1%) | 14 (25.9) | 11.767 | 0.003 |
 High | 10 | 2 (20.0%) | 8 (80.0%) |  |  |
Vascular invasion | |||||
 Absent | 45 | 28 (62.2%) | 17 (37.8%) | 1.272 | 0.259 |
 Present | 45 | 33 (73.3%) | 12 (26.7%) | ||
Tumor capsule | |||||
 Missing | 15 | 12 (80.0%) | 3 (20.0%) | 1.231 | 0.267 |
 Complete | 75 | 49 (65.3%) | 26 (34.7%) | ||
AFP (ug/l) | |||||
 ≤ 20 | 42 | 24 (57.1%) | 18 (42.9%) | 4.078 | 0.043 |
 > 20 | 48 | 37 (77.1%) | 11 (22.9%) | ||
HBsAg | |||||
 Negative | 17 | 9 (52.9%) | 8 (47.1%) | 2.112 | 0.146 |
 Positive | 73 | 52 (71.2%) | 21 (28.8%) | ||
Child–Pugh grade | |||||
 A | 70 | 46 (65.7%) | 24 (34.3%) | 0.614 | 0.433 |
 B | 20 | 15 (75.0%) | 5 (25.0%) | ||
BCLC stage | |||||
 A–B | 21 | 10 (47.6%) | 11 (52.4%) | 5.097 | 0.024 |
 C–D | 69 | 51 (73.9%) | 18 (26.1%) | ||